Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).

Abstract

Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection, a 'conversion therapy' strategy. However, conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed. Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice. Evidence review: Many research centers in China have accumulated significant experience implementing HCC conversion therapy. Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC; however, there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields. In order to summarize and learn from past experience and review current challenges, the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition) was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice. Sixteen consensus statements on the implementation of conversion therapy for HCC were developed. The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC.

• Authors: Hui-Chuan Sun, Jian Zhou, Zheng Wang, Xiufeng Liu, Qing Xie, Weidong Jia, Ming Zhao, Xinyu Bi, Gong Li, Xueli Bai, Yuan Ji, Li Xu, Xiao-Dong Zhu, Dousheng Bai, Yajin Chen, Yongjun Chen, Chaoliu Dai, Rongping Guo, Wenzhi Guo, Chunyi Hao, Tao Huang, Zhiyong Huang, Deyu Li, Gang Li, Tao Li, Xiangcheng Li, Guangming Li, Xiao Liang, Jingfeng Liu, Fubao Liu, Shichun Lu, Zheng Lu, Weifu Lv, Yilei Mao, Guoliang Shao, Yinghong Shi, Tianqiang Song, Guang Tan, Yunqiang Tang, Kaishan Tao, Chidan Wan, Guangyi Wang, Lu Wang, Shunxiang Wang, Tianfu Wen, Baocai Xing, Bangde Xiang, Sheng Yan, Dinghua Yang, Guowen Yin, Tao Yin, Zhenyu Yin, Zhengping Yu, Bixiang Zhang, Jialin Zhang, Shuijun Zhang, Ti Zhang, Yamin Zhang, Yubao Zhang, Aibin Zhang, Haitao Zhao, Ledu Zhou, Wu Zhang, Zhenyu Zhu, Shukui Qin, Feng Shen, Xiujun Cai, Gaojun Teng, Jianqiang Cai, Minshan Chen, Qiang Li, Lianxin Liu, Weilin Wang, Tingbo Liang, Jiahong Dong, Xiaoping Chen, Xuehao Wang, Shusen Zheng, Jia Fan, Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association
• Journal: Hepatobiliary surgery and nutrition (Hepatobiliary Surg Nutr) Vol. 11 Issue 2 Pg. 227-252 (Apr 2022) ISSN: 2304-3881 [Print] China (Republic : 1949- )
• PMID: 35464283 (Publication Type: Journal Article, Review)
• Copyright: 2022 Hepatobiliary Surgery and Nutrition. All rights reserved.